Aggregation-Induced Emission (AIE) Probe-Labeled Nanotheranostics: A Mini-Review

Nanotheranostics integrate theranostic functions onto a single nanoscale platform, and have become a new approach in precision medicine. Nanotheranostics rely on probes. However, traditional fluorescent probes often exhibit aggregation-caused quenching (ACQ) when loaded at high concentrations onto nanocarriers, severely limiting their imaging performance. Aggregation-induced emission agents (AIEgens) offer a solution to this long-standing problem through their ability to enhance fluorescence during aggregation. This mini-review systematically outlines nanotheranostic systems based on aggregation-induced emission (AIE). We first introduce the basic mechanism of AIE (the limitation of molecular internal motion) and its advantages over traditional fluorescent probes. Then, we discuss the design strategies of AIE nanoprobes according to the types of nanocarriers (including liposomes, polymer nanoparticles, and self-assembling systems). Additionally, we emphasize the disease-specific AIE nanotheranostic designs tailored for pathological microenvironments such as tumors, neurodegenerative diseases, and inflammatory diseases. Finally, we conduct an in-depth analysis of the current challenges hindering clinical translation, and propose future AIE nanotheranostic technologies applicable to clinical practice and the direction for personalized medicine.